REPROCELL and Polyphron Announce Collaboration to Advance AI-Driven Human Tissue Research Using StemRNA™ iPSCs

Enabling Advanced iPSC-Based Research and AI Applications

REPROCELL’s StemRNA™ iPSCs are generated using proprietary, footprint-free StemRNA™ Reprogramming Technology and provide high-quality human iPSC materials for research and development applications. With iPSC lines derived from donors across diverse demographic and clinical backgrounds, REPROCELL’s portfolio provides a well-characterized source of human biological diversity to support Polyphron’s donor-diverse tissue models.

Polyphron will incorporate REPROCELL’s StemRNA™ iPSCs into its Tissue Testing Environments, which combine physical and simulated human biology in a closed-loop system.

Polyphron’s Tissue Foundry uses automated manufacturing and stem-cell biology to generate structured human tissues across donor backgrounds. Those tissues are exposed to controlled interventions and measured longitudinally using multiple biological readouts. The resulting tissue trajectories are used to train Polyphron’s Tissue World Models, which are designed to predict how tissue responds to genetic, chemical, biological, and environmental changes across donors.

By expanding the number and diversity of donor-derived iPSC lines available to the platform, the collaboration will support Polyphron’s efforts to model human biological variation at greater scale.

Polyphron is initially applying the platform to cardiac tissue, with liver following as an additional tissue system.

From Biological Data to Computational Innovation

AI systems are becoming increasingly capable of generating biological hypotheses, therapeutic candidates, and experimental designs. However, the ability to generate new ideas is advancing faster than the ability to test them in human biology.

Polyphron is building a verification substrate for the AI-driven biology ecosystem. Its platform connects AI models directly to living human tissue: models can generate predictions, test those predictions in donor-diverse tissue, learn from the resulting longitudinal trajectories, and improve over time. The companies will explore applications across biological research and drug discovery, leveraging experimental data to improve computational models and generate new insights into human biology.

REPROCELL’s iPSC technology provides a source of well-characterized human biological diversity for this system. Through the collaboration, REPROCELL and Polyphron aim to support the generation of high-quality human tissue data for model training, evaluation, drug discovery, safety assessment, and broader biological research.

Polyphron’s platform ultimately aims to predict human responses before clinical trials begin, showing how interventions may perform across biological diversity and identifying the biological states most likely to respond.

About REPROCELL

REPROCELL (Yokohama, Japan; TYO: 4978) supports scientists worldwide through stem cell and drug discovery services and products. Since its founding in 2003 by leading Japanese stem cell researchers, REPROCELL has provided technologies that support prize-winning research and enable new cell therapy development to improve human health. To find out more, visit www.reprocell.com or contact info-us@reprocellusa.com.

About Polyphron

Polyphron is building artificial human biology. The company combines automated tissue manufacturing and AI simulation to create a physical-and-simulated verification substrate for therapeutic hypotheses against living human biology. Polyphron is based in New York. For more information, visit www.polyphron.com or reach out at contact@polyphron.com.